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Abstract
Aim—Covalent conjugates consisting of
diverse antigens coupled to optimal num-
bers of monomethoxypolyethylene glycol
(mPEG) molecules have been shown to
suppress antigen specific antibody forma-
tion. In this study, the possibility was
examined that the same conjugates might
prevent experimental immune mediated
blepharoconjunctivitis (EC, formerly
EAC) which had been shown to be caused
by CD4+ T cells—that is, to cell mediated
immunity.
Methods—6–8 week old male Lewis rats
were used. The test groups of rats received
two intravenous injections, each of 300 µg,
of a conjugate of ovalbumin mPEG
(OVA(mPEG)11) in phosphate buVered
saline (PBS), 14 and 28 days before the
single immunisation with OVA in com-
plete Freund’s adjuvant. The rats were
challenged 3 weeks later by eye drops con-
taining OVA; 24 hours later they were sac-
rificed, and their eyes, blood, and lymph
nodes were harvested for histological
examination and determination of anti-
OVA antibody titres and levels of cellular
immunity. Two control groups received
PBS or OVA in PBS before immunisation.
Furthermore, the possibility that OVA(m-
PEG)11 may have induced OVA specific
suppressor cells was tested by establishing
the eVects of the co-transfer of spleno-
cytes from OVA(mPEG)11 treated rats
with OVA primed lymph node cells on the
manifestations of EC.
Results—Either PBS or OVA pretreated
rats, which had not received OVA(m-
PEG)11, developed high levels of antibodies
and cell mediated immune responses to
OVA, and application of eye drops led to
blepharoconjunctivitis with massive cellu-
lar infiltration. In contrast, pretreatment
with OVA(mPEG)11 prevented cellular in-
filtration into the lids and conjunctivas, as
well as the formation of detectable hu-
moral and cellular immunity against
OVA. Co-transfer of splenocytes from
OVA(mPEG)11 treated rats with OVA
primed lymph node cells suppressed the
cellular infiltration on application of OVA
on the conjunctiva.
Conclusions—These data indicate that
intravenous injection of OVA(mPEG)11
conjugates suppressed both humoral and
cellular immunity by the eVects of antigen
specific suppressor cells, thus leading to
the inhibition of development of EC.
(Br J Ophthalmol 1999;83:973–979)
Induction of antigen specific immunological
tolerance is a most attractive strategy for treat-
ing the corresponding immunological diseases.
Among experimental immunological therapeu-
tic strategies, one may cite treatment with
monoclonal anti-CD4 antibodies,1 antigen
feeding,2 or injection of peptides representing
the epitopes of the autoantigen in question.3 In
addition to the encouraging results in animals,
some of these procedures were demonstrated
to be also eVective in patients.4 5
Obviously antigen specific suppression of
deleterious immune responses is to be pre-
ferred over the other procedures. In fact,
suppression of primary immune responses has
been achieved by diVerent procedures—for
example, by intravenous injection of (i) mas-
sive doses of aggregate free antigen,6 (ii) conju-
gates of antigen and autologous ã globulins,7
(iii) recently by conjugates of the antigens in
question and optimal numbers of molecules of
polyethylene glycol (PEG).8
We established an disease model of blepha-
roconjunctivitis in Lewis rats utilising ovalbu-
min (OVA) as a model non-ocular antigen and
termed experimental immune mediated
blepharoconjunctivitis (EC, formerly EAC).9
This disease is transferable by in vitro stimu-
lated lymph node cells from OVA primed
rats9 10 as well as OVA specific CD4+ T cell
line,11 whereas little, if any, IgE was detected in
serum from antigen primed rats. In addition, a
large amount of IFN-ã was produced by lymph
node cells and this cell line.11 These data indi-
cated that EC is caused by Th1 type CD4+ T
cells (and/or IgG antibodies), while IgE is not
involved in the induction of EC.
Until recently, antigen monomethoxypoly-
ethylene glycol (mPEG) conjugates have been
used for specific suppression of antibody
responses. However, in this study we demon-
strated that antigen-(mPEG)11 conjugates were
also capable of suppressing cellular responses.
Hence, having established that cellular immu-
nity was dominantly involved in both induction
and eVector phases of EC in rats,9 10 we investi-
gated in the present study the eVects of tolero-
genic mPEG conjugates of the same antigen—
that is, OVA, on the suppression of cell
mediated blepharoconjunctivitis.
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Materials and methods
RATS
Six to 8 week old male Lewis rats were
purchased from Seac Yoshitomi, Fukuoka,
Japan and were maintained in a pathogen-free
animal facility at Kochi Medical School. All
animal procedures conformed to institutional
guidelines and to the ARVO resolution on use
of animals in research.
PREPARATION OF THE TOLEROGEN BY COUPLING
OVA TO MPEG
For the present study, mPEG (MW 5000) acti-
vated with cyanuric chloride and OVA (grade
V) were purchased from Sigma Immuno-
chemicals (St Louis, MO, USA) and converted
to the corresponding conjugate (OVA(m-
PEG)11) using cyanuric chloride as the cou-
pling agent, according to the procedure re-
ported previously.12 There was no diVerence in
endotoxin level between OVA and OVA(m-
PEG)11 (2.3 ng/ml).
SYNTHETIC OVA OVERLAPPING PEPTIDES
Thirty eight overlapping 15-mer peptides,
spanning the entire OVA sequence, were
synthesised following the multipin method13
based on the amino acid sequence of OVA
(Peptide Institute, Inc, Osaka, Japan). Each
peptide overlaps five amino acids.
IMMUNISATION
Each rat received in the left hind foot pad an
injection of 100 µl containing 100 µg of OVA
emulsified in complete Freund’s adjuvant
(CFA, Yatron, Tokyo, Japan). In some experi-
ments, bovine serum albumin (BSA, Sigma
Immunochemicals, St Louis, MO, USA) was
used instead of OVA as both immunising and
challenging antigen at the same dose and con-
centration to test whether the suppression is
antigen specific or not.
EXPERIMENTAL PROTOCOL FOR TESTING THE
IMMUNOSUPPRESSIVE CAPACITY OF OVA(MPEG)11
Pretreatment of rats with OVA(mPEG)11
Figure 1 illustrates the experimental procedure
used. Each rat received intravenously two
injections of 500 µl, each containing 300 µg of
OVA(mPEG)11, 28 and 14 days before immu-
nisation; each of two groups of control rats
received 500 µl of PBS or 300 µg of immunis-
ing OVA in the same volume. Three weeks after
immunisation, all rats were challenged with a
total of 250 µg of OVA by 50 µl of eye drops,
each drop consisting of a solution of 5 mg of
OVA per ml of PBS. Each group consisted of
three rats in each experiment and each experi-
ment was repeated four times.
EVects of splenocytes from OVA(mPEG)11 treated
rats on the induction of EC in rats receiving
lymph node cells from third party immunised rats
Cells from inguinal lymph nodes of OVA
primed rats were harvested between 14 and 21
days after immunisation. These cells (100
×106) were cultured for 3 days in 25 cm2 flask
(Nunc, Roskilde, Denmark) containing 10 ml
of RPMI1640 medium (Nikken, Osaka, Japan)
supplemented with 2 mM L glutamine, 5 ×10−5
M 2-mercaptoethanol (2-ME), 100 U/ml peni-
cillin, 100 µg/ml streptomycin, 50 µg/ml OVA,
and 10% fetal calf serum (FCS, ICN Biomedi-
cal Japan Co, Tokyo, Japan). At the end of the
3 day period, the stimulated cells were
harvested and washed three times.9 10 The
stimulated cells (30 ×106) were injected intra-
venously into syngeneic recipients either with
200 ×106 of splenocytes from naive rats, or
from rats which had been treated with
OVA(mPEG)11. As described in the preceding
paragraph, 4 days later the recipients’ eyes were
challenged by eye drops of the OVA solution,
and 24 hours later their eyes were enucleated
for histological examination.
COUNT OF INFILTRATED CELLS IN THE
CONJUNCTIVA
After clinical evaluation, the eyes including the
lids were fixed in 10% buVered formalin and
embedded in paraYn. Thick sections of 10 µm
were stained with haematoxylin and eosin, and
the infiltrated cells were counted in the palpe-
bral conjunctiva with an eye piece grid of 400×
magnification.9 10
ASSESSMENT OF CELLULAR RESPONSES
Cellular responses of immunised rats were
measured by the lymphocyte proliferation
assay. For each experiment, lymph nodes of
each group of rats were combined. Lym-
phocyte proliferation assays were performed in
quadruplicate utilising 96 flat bottom well
plates. Lymph node cells (3 ×105 cells/well)
were cultured in a final volume of 0.2 ml RPMI
medium supplemented with 5% FCS. The
cells were stimulated with (i) OVA or OVA(m-
Day –28
Intravenous injection
OVA (300 µg)
mPEG-OVA (300 µg)
PBS
Intravenous injection
OVA (300 µg)
mPEG-OVA (300 µg)
PBS
Immunisation
with OVA (100 µg)
Challenge OVA
by eye drops
eyes for histology
blood for antibody titre
lymph nodes for proliferation
assay and cytokine assay
Day –14 Day 0 Day 21 22
Sacrifice rats
Figure 1 Experimental protocol. Groups of two to three rats were injected intravenously twice with 300 µg of OVA,
OVA(mPEG)11, or PBS, 14 and 28 days before immunisation with 100 µg of OVA in CFA. Three weeks after
immunisation they were challenged by the ocular route with OVA by eye drops, and 1 day later they were sacrificed,
and their organs were used for assays.
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PEG)11 at concentrations of 0.1, 1, 10, 100
µg/ml, (ii) synthetic OVA overlapping peptides
at 20 µg/ml, and (iii) purified protein deriva-
tives (PPD, Japan BCG, Tokyo, Japan) at 5
µg/ml. After incubation of 72 hours at 37°C in
a humidified atmosphere with 5% carbon
dioxide, the cultures were pulsed for 16 hours
with 0.5 µCi/well of 3H-thymidine (Japan
Atomic Energy Research Institute, Tokai,
Japan). The cultured cells were then harvested
and their radioactivity was measured. The data
are expressed as stimulation indices (SI =
mean cpm in stimulated cultures/mean cpm in
unstimulated control cultures) or delta cpm
(mean cpm in stimulated cultures − mean cpm
in unstimulated control cultures). In addition
to cellular proliferative responses, production
of IFN-ã and IL-4 by stimulation with OVA in
the culture supernatant of lymph node cells
from three diVerent groups were tested using
commercial cytokine ELISA (BioSource Inter-
national, Camarillo, CA, USA) detailed in pre-
vious reports.10 11
ASSESSMENT OF HUMORAL RESPONSES
Serum was collected from each rat via cardiac
puncture at the time of sacrifice, and serum
levels of anti-OVA antibodies were determined
by direct ELISA. Briefly, OVA (500 ng/well)
was adsorbed on to 96 well plates for 2 hours at
37°C. The plates were washed with PBS-
Tween and serially diluted serum samples were
added to the wells. Thereafter, the plates
coated with the antibody were treated with
peroxidase conjugated anti-rat IgG and washed
Figure 2 Histological sections of the conjunctiva from rats pretreated with PBS (A, B),OVA(mPEG)11 (C,D), or OVA
(E, F). Sections were stained with haematoxylin and eosin.Magnifications were either ×160 (A, C, E) or ×320 (B,D, F).
Figure 3 The infiltrated cell number refers to the average
of infiltrated cells in the palpebral conjunctiva of rats treated
with OVA,OVA(mPEG)11, or PBS. The error bars indicate
standard errors. Each group consisted of 12 rats.
150
100
50
0
In
fi
lt
ra
te
d
 c
el
l n
u
m
b
er
OVA mPEG-OVA PBS
Suppression of EC by conjugates of the antigen and mPEG 975
before addition of the substrate, 3,3',5,5'-
tetramethylbenzidine base (TMB-ELISA,
Gibco BRL, Gaithersburg, MD, USA); finally
the optical densities (ODs) of the contents of
all wells were determined at 610 nm. For
detecting OVA specific IgE, the passive cutane-
ous anaphylaxis (PCA) method14 was used.
STATISTICAL ANALYSIS
Statistical comparison in each group was
performed by Student’s t test.
Results
INHIBITION OF DISEASE INDUCTION
As previously reported,9 the main feature of
EC is mononuclear cellular infiltration in the
conjunctiva. The severity of EC has been
assessed by counting infiltrated cells in the
palpebral conjunctiva, because severity of
clinical grading was in parallel with the
infiltrated cell number.9 As shown in Figure 2,
massive cellular infiltration was demonstrated
in PBS and OVA treated rats, while minimal
inflammatory cells were detected in OVA(m-
PEG)11 treated rats. The number of cells
infiltrated on challenge with OVA into the
palpebral conjunctivae of rats, which had been
pretreated with PBS, OVA, or OVA(mPEG)11,
are shown in Figure 3. The infiltrated cell
number of the group with OVA (average
infiltrated cell number (n)=113) was almost
identical to that of the control group (n=120).
By contrast, however, n for the group treated
with OVA(mPEG)11 was only 22—that is, it
was significantly lower than that for the two
other groups (p<0.01). No diVerences in
inflammatory cell numbers in the conjunctiva
among three groups of diVerent treatment
were detected in cases where BSA was used as
an immunising and challenging antigen (data
not shown).
INHIBITION OF CELLULAR AND HUMORAL
RESPONSES IN RATS PRETREATED WITH
OVA(MPEG)11
To investigate the eVects of treatment of
OVA(mPEG)11 on the immune responses, we
tested the levels of (i) cellular immunity by the
proliferation assay or cytokine production
(IFN-ã and IL-4) of lymph node cells, and (ii)
antibody responses by ELISA or PCA using
the sera. Representative data of three rats per
group were presented in Figures 4–6. Both cel-
lular proliferation (Figs 4 and 5) and IgG pro-
duction (Fig 6A) in response to OVA were
depressed in rats pretreated with OVA(m-
PEG)11, in relation to the levels of rats treated
with OVA or PBS. Inhibition of proliferative
responses was remarkable in immunodomi-
Figure 4 Proliferative response to OVA by lymph node
cells of rats pretreated with OVA(mPEG)11, OVA, or PBS,
and immunised with OVA. The draining lymph node cells
were harvested and tested for their capacity to proliferate.
The recorded data represent means of the values of
stimulation indices (SI) of cells of three rats of each group.
Similar results were obtained in three confirmatory
experiments. The combined mean cpm values in the
unstimulated control cultures of rats were between 465 and
503.
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Figure 5 Proliferative response to OVA peptides by lymph node cells of rats pretreated with OVA(mPEG)11 or PBS, and
immunised with OVA. The recorded data represent means of the values of stimulation indices (SI) of cells of two rats of
each group. Similar results were obtained in one more experiment. The combined mean cpm values in the unstimulated
control cultures of rats were 950 (PBS) and 1130 (OVA(mPEG)11).
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nant epitopes (Fig 5). There were a few
epitopes which exhibited higher stimulatory
eVects in response to OVA(mPEG)11 treated
cells than PBS treated cells (Fig 5). By
contrast, no significant diVerences in prolifera-
tive responses to PPD were noted among three
groups (0.248<p<0.480) (Fig 6B). Lymph
node cells from all three groups did not exhibit
any apparent proliferative responses against
OVA(mPEG)11 (data not shown). In addition
to cellular proliferative responses, production
of IFN-ã in the culture supernatant was
suppressed in OVA(mPEG)11 treated groups
compared with the other two groups (p<0.01)
(Fig 6C). It is of note that IL-4 and IgE were
below detectable levels by the assays used here
in all three groups (data not shown).
CO-TRANSFER OF SPLENOCYTES OF OVA(MPEG)11
TREATED RATS SUPPRESSED THE INDUCTION OF
EC BY TRANSFER OF OVA PRIMED LYMPH NODE
CELLS
To analyse the mechanism of tolerance in-
duced by treatment with OVA(mPEG)11,
splenocytes from OVA(mPEG)11 treated rats
were passively transferred together with OVA
primed lymph node cells, as outlined in the
Materials and methods section. The data
clearly show that the co-transfer of OVA(m-
PEG)11 treated splenocytes suppressed the
influx of inflammatory cells into the conjuncti-
vas compared with the co-transfer of spleno-
cytes from naive rats (p=0.040) (Fig 7).
Discussion
The published studies to date support the con-
clusion that administration of a conjugate of a
given antigen and an optimal number of
mPEG molecules induces suppression of anti-
bodies specific to the antigen in question. As
reported previously,9 in our experimental
model of blepharoconjunctivitis, cellular im-
munity, especially Th1 type cell mediated
immunity, appeared to be essential both in the
induction and eVector phases of this disease.
Hence, the aim of this study was to investigate
the possibility that administration of mPEG
conjugates of the corresponding antigen would
inhibit both the induction of antigen specific
cellular immunity and the consequent develop-
ment of the disease.
Indeed, the results of this study supported
the conclusion that pretreatment of rats with
OVA(mPEG)11 downregulated the induction of
Figure 6 (A) Measurement of OVA specific IgG by
ELISA in serum of rats pretreated with OVA(mPEG)11,
OVA, or PBS, and immunised with OVA. The sera were
collected at the time of sacrifice and assayed by ELISA.
The abscissa indicates the degree of dilution of the serum;
the ordinate represents absorbance at 610 nm. Similar
results were obtained in three other separate experiments.
(B) Proliferative responses against PPD by lymph node
cells of rats pretreated with OVA(mPEG)11, OVA, or PBS,
and subsequently immunised with OVA. Except for using
PPD instead of OVA, the procedure used was the same as
employed for the experiment illustrated in Figure 4; in
addition, the concentration of PPD was 5 µg/ml. (C)
Production of IFN-ã in the culture supernatant of OVA
primed lymph node cells from rats pretreated with
OVA(mPEG)11, OVA, or PBS by in vitro stimulation with
OVA.Y axis indicates the produced amount of IFN-ã
(pg/ml).
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Figure 7 Infiltrated cell number in the palpebral
conjunctivas of rats which received stimulated OVA primed
cells, and either naive splenocytes or splenocytes from rats
pretreated with OVA(mPEG)11 and subsequently treated
with OVA in CFA (Fig 1). Stimulated OVA primed cells
were transferred into recipients with splenocytes from either
naive rats or rats treated with OVA(mPEG)11. Four days
after cell transfer, the rats were challenged and 24 hours
later they were sacrificed for counting infiltrated cells in the
conjunctiva.
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both cellular and humoral immunity to OVA
(Figs 4–6), and consequently inhibited devel-
opment of OVA specific EC (Figs 2 and 3). To
test the possibility that the tolerance demon-
strated here by OVA(mPEG)11 treatment might
be due to a change in the presentation of pep-
tides, proliferative responses against OVA frag-
ments were performed to compare with those
treated with PBS. No fragments were selected
to be stimulatory for lymph node cells from
OVA(mPEG)11 treated rats (Fig 5), indicating
that this suppression may not be epitope
specific but rather protein specific. Interest-
ingly, OVA(mPEG)11 did not have stimulatory
eVects to lymphocytes sensitised with OVA
from rats pretreated with OVA(mPEG)11 intra-
venously. It is important to point out that
whereas in vitro proliferative responses to OVA
of lymph node cells from OVA(mPEG)11
treated rats were inhibited, the reactivity of
these cells to PPD was the same as that of
lymph node cells from OVA treated rats or
from the control group (Fig 6A). In addition,
the results that pretreatment with OVA(m-
PEG)11 did not suppress inflammatory cellular
infiltration in the conjunctiva when a third
party antigen BSA was used as an immunising
and challenging antigen, further support the
conclusion that antigen-mPEG conjugates
suppress the immune response in an antigen
specific manner.
Although some reports claim that intra-
venous injection of native antigen could induce
tolerance,15 16 this statement is not supported
by our attempt to induce tolerance by injection
of the native antigen, OVA (Figs 4–6). Since
this eVect may be dependent on the dose
and/or the physical state of antigens injected,
we investigated the eVect of diVerent doses by
intravenous injection of OVA, 2 µg, 200 µg, and
20 mg, in three groups of rats, following the
protocol shown in Figure 1. No diVerences in
either proliferative responses or disease grad-
ings (data not shown) were observed among
these three groups in relation to the control
group treated with PBS. Therefore, it is clear
that it is diYcult, if at all possible, to induce
tolerance by pretreatment with OVA, com-
pared with the successful suppression of the
antigen specific immune response by mPEG
antigen conjugates.
Recently, it was demonstrated that the
development of diseases induced by Th1 type
immune responses such as experimental auto-
immune uveoretinitis (EAU) could be inhib-
ited by augmentation of antigen specific Th2
type immune responses.17 18 To investigate the
possible involvement of augmentation of OVA
specific Th2 type immunity by OVA(mPEG)11
treatment, IL-4 production by lymph node
cells and IgE in the serum were tested. Neither
IL-4 or IgE was detected in OVA(mPEG)11
treated rats by the assays used here suggesting
that a systemic shift from Th1 type to Th2 type
was not likely to be involved in the tolerance
induced by treatment with OVA(mPEG)11.
Although production of IL-4 was not tested in
splenocytes from OVA(mPEG)11 treated rats
because these transferred cells were injected
without culture in vitro, it would be important
and interesting to investigate whether these
splenocytes are able to produce immunoregu-
latory cytokines such as IL-4 or TGF-â.
Using the experimental protocol shown in
Figure 1, it is not possible to establish
unequivocally if cellular immunity is involved
in the development of the disease, and if the
inhibitory eVects of treatment with OVA(m-
PEG)11 aVect mainly the cellular arm of the
immune response. To shed some light on this
question, we used a cell transfer system for
determination of the involvement of cellular
immunity. The development of disease, which
was induced by transfer of OVA primed lymph
node cells, was suppressed by co-transfer of
splenocytes from OVA(mPEG)11 treated rats
(Fig 7). This evidence may be interpreted as
indicating that splenocytes from rats, which
had been treated with OVA(mPEG)11, inhib-
ited the manifestation of the disease which
would have been induced by the exclusive
transfer of OVA primed lymph node cells.
Therefore, the proposed mechanism for induc-
tion of tolerance by pre-administration of
antigen-mPEG conjugates postulates that anti-
gen specific suppressor cells and/or their
suppressive factors inactivate the correspond-
ing antigen specific T helper cells.19 The data
about suppression in the eVector phase (Fig 7)
might be interpreted as being that this
suppression was eVective at the challenge site,
while the data during the induction phase (Figs
2 and 3) could be interpreted as being that this
suppression was induced in the draining lymph
nodes.
In conclusion, this study (i) confirms that
successful induction of antigen specific toler-
ance may be achieved by antigen-mPEG
conjugates, and (ii) extends this capacity of
mPEG conjugates to suppression of antigen
specific T cells as demonstrated by inhibition
of the development of EC by these cells.
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